XML 57 R51.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

Subsequent Events - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands |  |  |  |  | 3 Months Ended | 6 Months Ended
--- | --- | --- | --- | --- | --- | ---
Jul. 30, 2024 | Jul. 11, 2024 | Oct. 27, 2023 | Apr. 27, 2023 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023
Subsequent Event [Line Items] |  |  |  |  |  |  |
Warrants to purchase shares of common stock |  |  | 319,150 | 2,020,270 |  |  |
Proceeds from issuance of common stock upon public offering, net of issuance costs |  |  |  |  |  | $ 0 | $ 153,840
Subsequent Event | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |
Total potential milestone payments | $ 400,000 |  |  |  |  |  |
Development and regulatory milestone payment eligible to receive | 100,000 |  |  |  |  |  |
Subsequent Event | Maximum | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |
Payment of option exercise fee | $ 6,500 |  |  |  |  |  |
Follow On Public Offering |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |
Common stock price per share |  |  | $ 23.4999 | $ 18.4999 |  |  |
Proceeds from issuance of common stock upon public offering, net of issuance costs |  |  | $ 143,700 | $ 201,300 |  |  |
Proceeds from issuance of common stock net of underwriting discounts and commissions and other offering expenses |  |  | $ 134,600 | $ 188,700 |  |  |
Follow On Public Offering | Common Stock |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |
Issuance of common stock, net of issuance costs, shares |  |  | 5,797,872 | 8,858,121 | 8,858,121 |  | 8,858,121
Common stock offering price |  |  | $ 23.5 | $ 18.5 |  |  |
Warrants to purchase shares of common stock |  |  | 319,150 | 2,020,270 |  |  |
Follow On Public Offering | Subsequent Event |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |
Common stock price per share |  | $ 34.9999 |  |  |  |  |
Proceeds from issuance of common stock upon public offering, net of issuance costs |  | $ 302,400 |  |  |  |  |
Proceeds from issuance of common stock net of underwriting discounts and commissions and other offering expenses |  | $ 283,800 |  |  |  |  |
Follow On Public Offering | Subsequent Event | Common Stock |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |
Issuance of common stock, net of issuance costs, shares |  | 8,355,714 |  |  |  |  |
Common stock offering price |  | $ 35 |  |  |  |  |
Warrants to purchase shares of common stock |  | 285,715 |  |  |  |  |
Overallotment Option | Common Stock |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |
Issuance of common stock, net of issuance costs, shares |  |  | 797,872 | 1,418,920 |  |  |
Overallotment Option | Subsequent Event | Common Stock |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |
Issuance of common stock, net of issuance costs, shares |  | 1,127,142 |  |  |  |  |

X
- Definition Aggregate potential milestone payments. + References No definition available. + Details
Name: | idya_AggregatePotentialMilestonePayments
Namespace Prefix: | idya_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Development and regulatory milestone payment to be received. + References No definition available. + Details
Name: | idya_DevelopmentAndRegulatoryMilestonePaymentToBeReceived
Namespace Prefix: | idya_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Net proceeds from issuance of common stock. + References No definition available. + Details
Name: | idya_NetProceedsFromIssuanceOfCommonStock
Namespace Prefix: | idya_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Payment of option exercise fee. + References No definition available. + Details
Name: | idya_PaymentOfOptionExerciseFee
Namespace Prefix: | idya_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details
Name: | us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition The cash inflow from the additional capital contribution to the entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details
Name: | us-gaap_ProceedsFromIssuanceOfCommonStock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + References No definition available. + Details
Name: | us-gaap_SaleOfStockPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Price of a single share of a number of saleable stocks of a company. + References No definition available. + Details
Name: | us-gaap_SharePrice
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of new stock issued during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details
Name: | us-gaap_SubsequentEventLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=idya_BiocytogenPharmaceuticalsBeijingCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=idya_FollowOnPublicOfferingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |